

## Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8<sup>+</sup> T cells via TLR4 signaling

Chrystal M. Paulos, ... , Steven A. Rosenberg, Nicholas P. Restifo

*J Clin Invest.* 2007;117(10):3140-3140. <https://doi.org/10.1172/JCI32205C1>.

Corrigendum

Oncology

Original citation: *J. Clin. Invest.* 117:2197-2204 (2007). doi:10.1172/JCI32205. Citation for this corrigendum: *J. Clin. Invest.* 117:3140 (2007). doi:10.1172/JCI32205C1. During the preparation of the manuscript, two m symbols were omitted from the data on page 2203. The correct text appears below. Administration of rhIL-2 was performed by i.p. injection twice daily at 3.6-36 mg/dose for a total of 5 doses. Ultrapure LPS (1 mg i.v.; Invivogen) was administered 1 day after ACT. The authors regret the error.

Find the latest version:

<https://jci.me/32205C1/pdf>





## Corrigendum

### **Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8<sup>+</sup> T cells via TLR4 signaling**

Chrystal M. Paulos, Claudia Wrzesinski, Andrew Kaiser, Christian S. Hinrichs, Marcello Chieppa, Lydie Cassard, Douglas C. Palmer, Andrea Boni, Pawel Muranski, Zhiya Yu, Luca Gattinoni, Paul A. Antony, Steven A. Rosenberg, and Nicholas P. Restifo

Original citation: *J. Clin. Invest.* **117**:2197–2204 (2007). doi:10.1172/JCI32205.

Citation for this corrigendum: *J. Clin. Invest.* **117**:3140 (2007). doi:10.1172/JCI32205C1.

During the preparation of the manuscript, two  $\mu$  symbols were omitted from the data on page 2203. The correct text appears below.

Administration of rhIL-2 was performed by i.p. injection twice daily at 3.6–36  $\mu$ g/dose for a total of 5 doses. Ultrapure LPS (1  $\mu$ g i.v.; Invivogen) was administered 1 day after ACT.

The authors regret the error.

## Corrigendum

### **Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain**

Yi Dai, Shenglan Wang, Makoto Tominaga, Satoshi Yamamoto, Tetsuo Fukuoka, Tomohiro Higashi, Kimiko Kobayashi, Koichi Obata, Hiroki Yamanaka, and Koichi Noguchi

Original citation: *J. Clin. Invest.* **117**:1979–1987 (2007). doi:10.1172/JCI30951.

Citation for this corrigendum: *J. Clin. Invest.* **117**:3140 (2007). doi:10.1172/JCI30951C1.

During the preparation of the manuscript, the doses of ET-18-OCH<sub>3</sub>, U73122, and GF were incorrectly reported in the legend for Figure 3. The correct sentence appears below.

In some experiments, the bath solution was perfused with either a PLC inhibitor – ET-18-OCH<sub>3</sub> (ET; 2  $\mu$ M) or U73122 (2  $\mu$ M) – or a PKC inhibitor, GF (0.5  $\mu$ M or 10  $\mu$ M) 120 seconds before SL-NH<sub>2</sub> reapplication.

The authors regret the error.